It should be noted that within each malignancy, other genetic mutations have been identified conferring resistance to ibrutinib; however, the BTK and PLCG2 mutations are the most common in patients with CLL. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.